Print Page  Close Window

Press Release
Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark Fitzpatrick, president and CEO, and Dr. William Ludlam, SVP, clinical development and medical affairs, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 4:10 p.m. ET.

A live and archived audio webcast of the presentation will be available under the News & Investors section of Chiasma’s website at www.chiasma.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.

About Chiasma

Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The Company recently initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following SPA agreement with the FDA on the design of the trial. Chiasma is headquartered in Waltham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.

Contact:
Andrew Blazier
Sharon Merrill Associates
(617) 542-5300
chma@investorrelations.com

Primary Logo

Chiasma, Inc.